Merck Global Health Innovation Fund

Merck Global Health Innovation Fund (Merck GHI) operates as the strategic corporate venture capital arm of Merck & Co., Inc., a leading global pharmaceutical company. Established to identify and invest in groundbreaking healthcare technology and digital health solutions, Merck GHI's primary objective is to foster innovation that aligns with and complements Merck's broader mission of improving human health. The fund seeks out companies developing advanced solutions in areas such as artificial intelligence, data analytics, digital therapeutics, remote patient monitoring, and patient engagement platforms, aiming to enhance healthcare delivery and patient outcomes.

Unlike traditional financial VCs, Merck GHI emphasizes strategic partnerships and collaborations with its portfolio companies. Beyond capital infusion, the fund offers access to Merck's extensive industry expertise, global network, regulatory insights, and research and development capabilities. This collaborative approach is designed to accelerate the growth and market adoption of innovative technologies, creating synergistic value for both the startups and Merck's core business. Since its inception, Merck GHI has built a robust portfolio, having made over 70 investments in various healthcare technology companies globally, demonstrating its commitment to shaping the future of health.

Merck GHI typically targets early to growth-stage companies, often participating in Series A and B funding rounds. While specific check sizes can vary based on the opportunity and strategic fit, their initial investments generally range from approximately $2 million to $15 million. This allows them to take meaningful stakes in promising ventures while leaving room for follow-on investments as companies mature. The fund's long-term vision is to contribute to the evolution of the healthcare ecosystem by supporting disruptive technologies that have the potential for significant impact on global health.